The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A Beckett, Nigel J. Cairns, Robert C. Green, Danielle J Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Jennifer Salazar, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, John Q. Trojanowski

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2016

Keywords

  • Alzheimer's disease
  • Amyloid phenotyping
  • Brain Health Registry
  • Centiloid method
  • Clinical trial biomarkers
  • Functional connectivity
  • Tau imaging

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement'. Together they form a unique fingerprint.

  • Cite this

    Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Salazar, J., Saykin, A. J., Shaw, L. M., Toga, A. W., & Trojanowski, J. Q. (Accepted/In press). The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2016.10.006